Colleen Cutcliffe Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome Inc. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Whole Biome, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
Adam D’Augelli Adam D'Augelli has been on the Board of Directors of Whole Biome since 2013. Adam is a Partner at True Ventures. Growing up, Adam was drawn to startups and technology – early on as a founder of a donation–based record label and a social business in India, then later as a consultant to early-stage technology companies on the East Coast. Building upon this experience, Adam led the creation of "Digital Frontiers," a course at the University of Florida exploring how the Internet and technology are changing the global business landscape. Adam graduated magna cum laude from the University of Florida with a BS and MS in Finance, and was selected as one of the two Four Year Outstanding Scholars in his graduating class. Outside the office, Adam can be found at live music events both inside and outside of San Francisco, participating in half marathons, or reading GigaOM Pro Reports in Golden Gate Park.
Hugh Martin Hugh Martin is the Chairman of the Board of Directors for Whole Biome and has been on the BoD since its inception in 2013. Hugh is the CEO of Sensity Systems. His 35-year track record as an entrepreneurial leader of cutting-edge technology companies, new ventures, and high-growth businesses includes serving at the helm of numerous highly successful organizations. In 2011, he was named CEO for Fortune magazine’s ‘Executive Dream Team: The startup edition,’ acknowledged for his ‘management chops’ and for successfully taking public two companies, in two different industries.
Prior to Sensity, Hugh was chairman and CEO of Pacific Biosciences, a leading company in third-generation DNA sequencing. He founded Pacific Biosciences in 2004 with a team from Cornell University and piloted the company through its IPO in 2010 and commercialization in 2011. Before that, he was chairman, president, and CEO of ONI Systems, a high-speed optical telecommunications systems company he founded in 1998 and took public in 2000. Named the Fastest Growing Company in Silicon Valley in 2001, ONI was sold to Ciena in 2002; Hugh then served as a consultant to Ciena. During his career, Hugh also was president and director of 3DO, an interactive gaming company; served as a CEO-in-residence at the venture capital firm of Kleiner Perkins Caufield & Byers; and ran desktop engineering for Apple Computer. Earlier, he was one of the first employees of Ridge Computers, where he helped design one of the world’s first commercial reduced instruction set computing (RISC) minicomputers. He earned a BS in electrical engineering from Rutgers, the State University of New Jersey-New Brunswick.
John Eid John Eid is the CSO and Co-Founder of Whole Biome Inc. John has led fundamental technology development for over a decade in diverse areas that include advanced microscopy, single molecule detection and analyses, automated data acquisition systems, biophysical system modeling, and genome sequencing applications. Prior to co-founding Whole Biome, John was a Principal Scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.
Dietrich Stephan Dietrich Stephan has been on the Board of Directors for Whole Biome since its inception in 2013. Dietrich is the Professor and Chair of the Department of Human Genetics at the University of Pittsburgh Graduate School of Public Health. Dietrich is an American human geneticist and entrepreneur who works in personalized medicine, has published more than 140 peer-reviewed scientific articles in the scientific literature and served as the Chairman of the NIH Neuroscience Microarray Consortium for seven years. He sits on the Board of Directors of a number of non-profit academic institutions such as Sage Bionetworks and the Personalized Medicine Coalition.
Prior to joining the University of Pittsburgh, Dietrich co-founded Navigenics, a personal genetics testing company, with oncologist Dr. David Agus. Dietrich also founded Amnestix, a pharmaceutical company that focuses on the treatment of learning and memory impairment as caused by a number of conditions such as Alzheimer's disease and aging. Dietrich co-founded Aueon, Inc. with Vern Norviel in 2009, a biotechnology company focused on providing early cancer diagnostic tests to appropriately select the most effective chemotherapeutic agents. In 2011, Dietrich founded a next-generation genome sequencing and interpretation company named Silicon Valley Biosystems (now Lifecode). In 2013, Dietrich founded and is Chairman of the Board of DiaVacs Inc, which is a pharmaceutical company based on a proprietary platform technology that utilizes dendritic cell therapy together with a mechanistic understanding of the immune system to cure antigen-specific autoimmune disorders. In 2003, Dietrich worked at Translational Genomics Research Institute (TGen) as a Senior Investigator and founding Chairman of the Department of Neurogenomics. He later served as the Deputy Director of Discovery Research at TGen. His laboratory has identified the genetic basis of 20 single gene disorders, and several dozen complex genetic disorders using high-throughput technologies and strategies. Dietrich has also worked on the provider side of healthcare, having implemented personalized genomic medicine clinical programs with sustainable business models in many provider systems. Dietrich crafted the business case and obtained the initial funding for the Gene Partnership Project at Children's Hospital Boston and Harvard Medical School. Dr. Stephan received his B.S. in Biology/Biochemistry from Carnegie Mellon University and his Ph.D. in Human Molecular Genetics from the University of Pittsburgh.
Peter Barton Hutt Peter Barton Hutt joined the Board of Directors for Whole Biome in 2016. Peter is a senior counsel in the Washington, DC law firm of Covington & Burling, specializing in Food and Drug Law. He began his law practice with the firm in 1960 and, except for his four years in the government, has continued at the firm ever since. From 1971 to 1975 he was Chief Counsel for the Food and Drug Administration.
Since 1994, Peter has taught a full course on Food and Drug Law during Winter Term at Harvard Law School. Peter is the co-author of Food and Drug Law: Cases and Materials (Foundation Press, 1st edition 1980, 2d edition 1991, 3d edition 2007) and has published more than 175 book chapters and articles on Food and Drug Law and on health policy. He is a member of the Editorial Advisory board of the Food and Drug Law Journal.
Peter has represented the national trade associations for the food, prescription drug, nonprescription drug, dietary supplement, and cosmetic industries. While at FDA he drafted the legislation that became the Medical Device Amendments of 1976, and beginning in 1962 he has participated in the drafting of most of the major legislation amending the Federal Food, Drug, and Cosmetic Act. He has testified before the House and Senate more than 100 times either as a witness or as counsel accompanying a witness. Peter has been a member of the Institute of Medicine of the National Academy of Sciences since it was formed in 1971.
Peter was named by The Washingtonian magazine as one of Washington's 50 best lawyers (out of more than 40,000) and as one of Washington's 100 most influential people; by the National Law Journal as one the 40 best health care lawyers in the United States; and by Global Counsel as the best FDA regulatory specialist in Washington, DC. Business Week referred to Peter in June 2003 as the "unofficial dean of Washington food and drug lawyers." In naming Peter in September 2005 as one of the eleven best food and drug lawyers, the Legal Times also referred to him as "the dean of the food-and-drug bar." In April 2005, he was presented the Distinguished Alumni Award by FDA. In May 2005, he was given the Lifetime Achievement Award for research advocacy by the Foundation for Biomedical Research. The Best Lawyers in America selected Peter as the 2013 FDA Lawyer of the Year for Washington, DC. Peter received his B.A. from Yale University, his LL.B. from Harvard Law School and his LL.M. from the New York University School of Law.